金斯瑞蓬勃生物是全球快速的抗体人源化服务供应商,通过CDR移植和回复突变,12天就能产生亲和力高于或与嵌合抗体相当人源化抗体。金斯瑞蓬勃生物将基于MOE等正版授权分析软件,为客户提供包括免疫原性,翻译后修饰(PTM)和抗体聚集的成药性预测报告。
在抗体早期发现阶段进行成药性预测,可降低获得存在成药性风险分子的概率!金斯瑞蓬勃生物在抗体人源化阶段为客户提供包含免疫原性,翻译后修饰以及抗体聚集的成药性预测报告。基于成药性预测,金斯瑞蓬勃生物可以提供成药性优化服务,助力客户在进入CMC之前获得更优的抗体分子。
samples | Chi² (RU²) | ka (1/Ms) | kd(1/s) | KD (M) | Rmax (RU) |
---|---|---|---|---|---|
humanized antibody | 5.03E-02 | 3.67E+05 | 6.90E-05 | 1.88E-10 | 70.5 |
parental antibody | 2.11E-01 | 4.02E+05 | 5.56E-05 | 1.38E-10 | 73.6 |
Table.1 Affinity kinetic analysis
Fig.1 Affinity kinetic analysis of humanized antibody
人源化抗体和亲本抗体ELISA检测结合活性如图所示,在抗体人源化改造前后EC50值,上下平台值高度相似。
Fig.2 Comparison of the affinity of humanized antibodies to parental antibody
人源化抗体和亲本抗体FACS检测结合活性如图所示,在抗体人源化改造前后EC50值,上下平台值高度相似。
Fig.3 Comparison of the affinity of humanized antibodies to parental antibody
“We are pleased with the antibody humanization service and the purification service of ProBio. It is very impressive and professional. we validated the humanization service by testing the antibody against anti-human IgG as the secondary antibody. The humanized antibody purification met our expectations and need. The characterization of the antibody that was highlighted by the COA is excellent. We would continue to avail your service and will also recommend it to anyone who needs such service. Thanks.” – Govind Panchamoorthy, Director, Genus Oncology
为了能够高效而准确提供报价,请首先下载并完成询价咨询表,然后填写完整的询价表通过邮件发送给我们,我们将在第一时间内给您答复。